[go: up one dir, main page]

WO2010113183A3 - Process for the preparation of 1-[[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]sulfonyl] pyrrolidine and its pharmaceutically acceptable salts - Google Patents

Process for the preparation of 1-[[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]sulfonyl] pyrrolidine and its pharmaceutically acceptable salts Download PDF

Info

Publication number
WO2010113183A3
WO2010113183A3 PCT/IN2010/000216 IN2010000216W WO2010113183A3 WO 2010113183 A3 WO2010113183 A3 WO 2010113183A3 IN 2010000216 W IN2010000216 W IN 2010000216W WO 2010113183 A3 WO2010113183 A3 WO 2010113183A3
Authority
WO
WIPO (PCT)
Prior art keywords
indol
pyrrolidine
sulfonyl
dimethylamino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2010/000216
Other languages
French (fr)
Other versions
WO2010113183A2 (en
Inventor
Manne Satyanarayana Reddy
Sajja Eswaraiah
Maramreddy Sahadeva Reddy
Komati Satyanarayana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSN Laboratories Pvt Ltd
Original Assignee
MSN Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSN Laboratories Pvt Ltd filed Critical MSN Laboratories Pvt Ltd
Publication of WO2010113183A2 publication Critical patent/WO2010113183A2/en
Publication of WO2010113183A3 publication Critical patent/WO2010113183A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A process for preparation of 1-[[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine of Formula (1), which is commonly known as Almotriptan, and its pharmaceutically acceptable salts is provided. The required purity of almotriptan malate free of impurities is attained in three different ways, including by preparing the acid addition salts of amino indole compound, by proceeding through the almotriptan succinate and by specific purification of almotriptan malate from a suitable solvent.
PCT/IN2010/000216 2009-04-03 2010-04-01 Process for the preparation of 1-[[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]sulfonyl] pyrrolidine and its pharmaceutically acceptable salts Ceased WO2010113183A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN774/CHE/2009 2009-04-03
IN774CH2009 2009-04-03
IN546CH2010 2010-03-03
IN546/CHE/2010 2010-03-03

Publications (2)

Publication Number Publication Date
WO2010113183A2 WO2010113183A2 (en) 2010-10-07
WO2010113183A3 true WO2010113183A3 (en) 2010-12-29

Family

ID=42828790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000216 Ceased WO2010113183A2 (en) 2009-04-03 2010-04-01 Process for the preparation of 1-[[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]sulfonyl] pyrrolidine and its pharmaceutically acceptable salts

Country Status (1)

Country Link
WO (1) WO2010113183A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085723A1 (en) * 2010-12-20 2012-06-28 Orchid Chemicals And Pharmaceuticals Limited A process for the purification of almotriptan acid addition salt
EP2673262B1 (en) 2011-02-10 2021-11-03 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
CN102827062A (en) * 2012-09-17 2012-12-19 扬子江药业集团四川海蓉药业有限公司 Method for preparing almotriptan malate
EP2774605A1 (en) 2013-02-06 2014-09-10 Galenicum Health S.L. Pharmaceutical composition comprising almotriptan malate having uniform drug distribution and potency
CN103353494B (en) * 2013-07-04 2014-12-31 山东省医药工业研究所 HPLC (high performance liquid chromatography) detection method of related substances in almotriptan malate
CN106478484B (en) * 2016-08-31 2017-11-10 重庆华森制药股份有限公司 A kind of method for preparing almotriptan key intermediate
CN106397359B (en) * 2016-08-31 2017-12-05 重庆华森制药股份有限公司 The preparation method of almotriptan intermediate 4 (1 pyrrolidinyl sulfonymethyl) phenylhydrazine
CN109928910B (en) * 2017-12-19 2022-07-22 上海医药工业研究院 Preparation method of anti-migraine drug almotriptan

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013098A1 (en) * 2005-07-25 2007-02-01 Matrix Laboratories Limited A process for the preparation of almotriptan
WO2008151584A1 (en) * 2007-06-13 2008-12-18 Zentiva, A.S. Method for the preparation of high purity almotriptan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013098A1 (en) * 2005-07-25 2007-02-01 Matrix Laboratories Limited A process for the preparation of almotriptan
WO2008151584A1 (en) * 2007-06-13 2008-12-18 Zentiva, A.S. Method for the preparation of high purity almotriptan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUMAR, A. PHANI ET AL.: "A Validated Reversed Phase HPLC Method for the Determination of Process-Related Impurities in Almotriptan Malate API.", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 46, 2008, pages 792 - 798 *

Also Published As

Publication number Publication date
WO2010113183A2 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
WO2010113183A3 (en) Process for the preparation of 1-[[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]sulfonyl] pyrrolidine and its pharmaceutically acceptable salts
WO2007103456A3 (en) Piperazine and piperidine biaryl derivatives
NZ600210A (en) Substituted 4-aminocyclohexane derivatives
WO2010076810A3 (en) A process for the preparation of gefitinib
GEP20125621B (en) 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor
WO2011128784A3 (en) Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof
WO2010062590A3 (en) Process for the preparation of protected l-alanine derivatives
WO2011022596A3 (en) Preparation of bazedoxifene and its salts
WO2009047499A3 (en) Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
WO2010116140A8 (en) New process for preparing hydroxylamines and medicaments
WO2008045777A3 (en) A process for the preparation of benzimidazole derivatives and their salts
WO2007102567A1 (en) Process for production of 3,4-disubstituted pyrrolidine derivative and intermediate for the production
NZ600266A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2008079266A3 (en) Synthesis of pyrrolidine compounds
PH12012501974A1 (en) Novel hypoglycemic compounds
WO2008099286A3 (en) Improved process for preparing ethyl (s)-2-ethoxy-4-[n-[1-(2- piperidinophenyl)-3-methyl-1-butyl]aminocarbonyl methyl]benzoate and use thereof for the preparation of repaglinide
MX2010009876A (en) New process for the preparation of cyclohexanecarboxylic acid derivatives via the corresponding cyclohexanecarboxamide derivative.
WO2009075516A3 (en) Process for preparing pantoprazole sodium sesquihydrate
MX2010009926A (en) New process for the preparatiion of cyclohexanecarboxylic acid dericatives.
WO2009021943A3 (en) Novel preparation process
WO2008126106A3 (en) Novel and improved processes for the preparation of intermediates of darifenacin, darifenacin and its pharmaceutically acceptable salts
MXPA05003696A (en) New process for synthesizing derivatives of 1,3,4,5-tetrahydro-2h-3-benzazepin-2-one and its application to the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts.
CN102964307B (en) Dabigatran etexilate related substance and preparation method thereof
WO2012004811A8 (en) Process for the preparation of 5-substsituted indole derivative
WO2006114676A3 (en) A process for the preparation of rupatadine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10758153

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10758153

Country of ref document: EP

Kind code of ref document: A2